Thyroid Nodules: Is HIFU Ablation the Future of Treatment?
"A new study explores whether High-Intensity Focused Ultrasound (HIFU) can rival traditional surgery for benign thyroid nodules, offering potentially scar-free, quicker recovery."
Thyroid nodules are a common occurrence, and while most are harmless, some can grow large enough to cause discomfort or even difficulty swallowing. When this happens, doctors often recommend surgical removal. However, surgery isn't without its drawbacks: it can lead to complications, requires general anesthesia, and leaves a scar.
Enter High-Intensity Focused Ultrasound (HIFU) ablation, a non-invasive technique that's gaining traction as a potential alternative. HIFU uses focused sound waves to heat and destroy the nodule, all without making a single incision. But how does it stack up against traditional surgery?
A recent study published in the journal Surgery sought to answer this question by comparing the outcomes of HIFU ablation and open lobectomy (surgical removal of the thyroid lobe) in patients with benign thyroid nodules. By using a method called propensity score matching, the researchers were able to create two groups of patients that were similar in terms of age, sex, and other important factors, allowing for a more accurate comparison of the two treatments.
Current Outcomes
HIFU ablation is described as a safe, minimally invasive treatment for benign symptomatic thyroid nodules, but reported outcomes vary. One study found volume reduction of 20–46% at six months, and 31% of patients ultimately required surgery. Another report found average volume reduction ratios of 48.55% at six months and 55.02% at 12 months, with low rates of complications including vocal fold paresis, Horner’s syndrome, recurrent laryngeal nerve palsy, hypothyroidism, and skin redness.
Current Treatment Landscape
Surgery remains the gold standard for symptomatic benign and/or malignant thyroid nodules, while radiofrequency ablation has emerged as a minimally invasive option for high-risk patients and people who decline surgery. HIFU is presented as a promising non-invasive technique for benign thyroid nodules, with ongoing attention to its safety, efficacy, limitations, and future implications. Its use can be technically difficult in people with short, thick necks or partially retrosternal nodules because positioning the lens may be complex and time-consuming.
From Surgery to Thermal Ablation
Thyroid nodules are common, and most are benign, although some require treatment because they continue to grow or cause undesirable symptoms. Several minimally invasive thermal ablation techniques were introduced to address complications associated with traditional methods such as surgery. HIFU was identified as one of these emerging approaches for thyroid nodule ablation.
HIFU vs. Surgery: Key Findings at a Glance
The study compared the clinical outcomes of patients who underwent high-intensity focused ultrasound (HIFU) ablation with those who had open lobectomy. Here's a breakdown of what they discovered:
- Shorter Treatment & Hospital Stay: HIFU ablation took less time to perform than surgery.
- Reduced Costs: The medical costs associated with HIFU ablation were significantly lower than those for surgery.
- Effective Nodule Shrinkage: HIFU ablation resulted in a significant reduction in nodule size, with an average shrinkage of 64% after six months.
- Similar Symptom Improvement: Patients in both groups reported comparable improvements in their symptoms after treatment.
- Voice Quality Maintained: Acoustic parameters of voice were unchanged after both procedures.
Recent Evidence
A three-year retrospective multicenter follow-up study reported median nodule volume reductions of 31.5% at 12 months and 31.9% at 36 months. In that study, technical efficacy was obtained in 17.2% of cases at six months, 17.8% at 12 months, 3.4% at 24 months, and 7.4% at 36 months. A separate 2023 study evaluated HIFU’s effectiveness and safety for benign thyroid nodules, including volume reduction and treatment success.
Evidence Gaps
Available evidence has largely come from a limited number of specialized centers, and one review called for larger-scale, multicenter, prospective trials to confirm HIFU’s safety and efficacy. A systematic review and meta-analysis covering studies from 1990 to 2021 found significant heterogeneity in pooled volume reduction ratios at three, six, and 24 months. No studies in that analysis recorded complete disappearance of the nodules. NICE concluded that there were no major safety concerns, but described the evidence for efficacy as limited in quantity and quality.
Comparing Ablation Modalities
Research has directly compared radiofrequency ablation and microwave ablation for benign thyroid nodules, focusing on their effectiveness and complication rates. A 2021 study searched PubMed, Embase, and Cochrane databases through September 11, 2020, to compare the effectiveness and safety of these two methods. Another study evaluated a non-cooled microwave ablation system against a radiofrequency ablation system. These sources establish the comparative focus but do not provide specific outcome figures in the supplied material.
The Future of Thyroid Nodule Treatment?
While this study offers promising insights into the potential of HIFU ablation, it's important to remember that it's not a one-size-fits-all solution. The decision of whether to undergo HIFU ablation or surgery should be made in consultation with a doctor, taking into account individual factors such as nodule size, location, and patient preferences. However, as technology advances and more research becomes available, HIFU ablation may become an increasingly attractive option for those seeking a less invasive approach to thyroid nodule treatment.
Balancing Promise and Proof
HIFU is characterized as an emerging thermal ablation technique that has been applied to benign thyroid nodules. A systematic review and meta-analysis reported pooled volume reduction ratios of 17.59% at one month, 48.93% at three months, and 60.43% at six months, with corresponding 95% confidence intervals of 12.56–22.62, 42.20–55.66, and 51.88–68.98. The broader evidence base also includes a systematic review and network meta-analysis of randomized controlled trials comparing different ultrasound-guided ablation methods. Together, these sources support continued evaluation of HIFU while indicating that its place among ablation options depends on comparative evidence.